336 related articles for article (PubMed ID: 28661054)
1. Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation.
Smoot RL; Werneburg NW; Sugihara T; Hernandez MC; Yang L; Mehner C; Graham RP; Bronk SF; Truty MJ; Gores GJ
J Cell Biochem; 2018 Jan; 119(1):824-836. PubMed ID: 28661054
[TBL] [Abstract][Full Text] [Related]
2. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
[TBL] [Abstract][Full Text] [Related]
3. YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.
Sugihara T; Werneburg NW; Hernandez MC; Yang L; Kabashima A; Hirsova P; Yohanathan L; Sosa C; Truty MJ; Vasmatzis G; Gores GJ; Smoot RL
Mol Cancer Res; 2018 Oct; 16(10):1556-1567. PubMed ID: 29903769
[TBL] [Abstract][Full Text] [Related]
4. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
Conboy CB; Yonkus JA; Buckarma EH; Mun DG; Werneburg NW; Watkins RD; Alva-Ruiz R; Tomlinson JL; Guo Y; Wang J; O'Brien D; McCabe CE; Jessen E; Graham RP; Buijsman RC; Vu D; de Man J; Ilyas SI; Truty MJ; Borad M; Pandey A; Gores GJ; Smoot RL
J Hepatol; 2023 Jan; 78(1):142-152. PubMed ID: 36162702
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.
Saikawa S; Kaji K; Nishimura N; Seki K; Sato S; Nakanishi K; Kitagawa K; Kawaratani H; Kitade M; Moriya K; Namisaki T; Mitoro A; Yoshiji H
Cancer Lett; 2018 Oct; 434():120-129. PubMed ID: 30031758
[TBL] [Abstract][Full Text] [Related]
6. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
7. Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2-Platelet-Derived Growth Factor Receptor Beta-Yes-Associated Protein Signaling Axis.
Luo X; Campbell NA; He L; O'Brien DR; Singer MS; Lemjabbar-Alaoui H; Ahn KS; Smoot R; Torbenson MS; Rosen SD; Roberts LR
Hepatology; 2021 Sep; 74(3):1411-1428. PubMed ID: 33735525
[TBL] [Abstract][Full Text] [Related]
8. YAP is a critical oncogene in human cholangiocarcinoma.
Pei T; Li Y; Wang J; Wang H; Liang Y; Shi H; Sun B; Yin D; Sun J; Song R; Pan S; Sun Y; Jiang H; Zheng T; Liu L
Oncotarget; 2015 Jul; 6(19):17206-20. PubMed ID: 26015398
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.
Tóth M; Wehling L; Thiess L; Rose F; Schmitt J; Weiler SME; Sticht C; De La Torre C; Rausch M; Albrecht T; Grabe N; Duwe L; Andersen JB; Köhler BC; Springfeld C; Mehrabi A; Kulu Y; Schirmacher P; Roessler S; Goeppert B; Breuhahn K
BMC Cancer; 2021 Oct; 21(1):1079. PubMed ID: 34615513
[TBL] [Abstract][Full Text] [Related]
10. Targeting PDGFR-β in Cholangiocarcinoma.
Fingas CD; Mertens JC; Razumilava N; Bronk SF; Sirica AE; Gores GJ
Liver Int; 2012 Mar; 32(3):400-9. PubMed ID: 22133064
[TBL] [Abstract][Full Text] [Related]
11. YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers.
Galli GG; Carrara M; Yuan WC; Valdes-Quezada C; Gurung B; Pepe-Mooney B; Zhang T; Geeven G; Gray NS; de Laat W; Calogero RA; Camargo FD
Mol Cell; 2015 Oct; 60(2):328-37. PubMed ID: 26439301
[TBL] [Abstract][Full Text] [Related]
12. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
[TBL] [Abstract][Full Text] [Related]
13. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.
Wang Z; Wu Y; Wang H; Zhang Y; Mei L; Fang X; Zhang X; Zhang F; Chen H; Liu Y; Jiang Y; Sun S; Zheng Y; Li N; Huang L
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E89-98. PubMed ID: 24367099
[TBL] [Abstract][Full Text] [Related]
14. The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies.
Werneburg N; Gores GJ; Smoot RL
Gene Expr; 2020 Jun; 20(1):67-74. PubMed ID: 31253203
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.
Artinian N; Cloninger C; Holmes B; Benavides-Serrato A; Bashir T; Gera J
J Biol Chem; 2015 Aug; 290(32):19387-401. PubMed ID: 25998128
[TBL] [Abstract][Full Text] [Related]
16. YAP and the Hippo pathway in cholangiocarcinoma.
Sugihara T; Isomoto H; Gores G; Smoot R
J Gastroenterol; 2019 Jun; 54(6):485-491. PubMed ID: 30815737
[TBL] [Abstract][Full Text] [Related]
17. The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma.
Buckarma EH; Werneburg NW; Conboy CB; Kabashima A; O'Brien DR; Wang C; Ilyas SI; Smoot RL
Mol Cancer Res; 2020 Oct; 18(10):1574-1588. PubMed ID: 32646966
[TBL] [Abstract][Full Text] [Related]
18. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1.
Si Y; Ji X; Cao X; Dai X; Xu L; Zhao H; Guo X; Yan H; Zhang H; Zhu C; Zhou Q; Tang M; Xia Z; Li L; Cong YS; Ye S; Liang T; Feng XH; Zhao B
Cancer Res; 2017 Sep; 77(18):4868-4880. PubMed ID: 28754671
[TBL] [Abstract][Full Text] [Related]
19. The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.
Ma W; Han C; Zhang J; Song K; Chen W; Kwon H; Wu T
Hepatology; 2020 Oct; 72(4):1283-1297. PubMed ID: 31990985
[TBL] [Abstract][Full Text] [Related]
20. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]